Intellistem Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- (Cancelled)
- Investors
-
4
Intellistem General Information
Description
Operator of a biotechnology platform designed to develop cell-based therapeutics for cancer treatment. The company offers non-engineered, off-the-shelf SSC Gamma Delta Cells that work synergistically with standard antibody therapies, enabling cancer treatment providers to improve therapeutic efficacy.
Contact Information
Website
www.intellistemtech.comCorporate Office
- 440 Davis Court
- Suite 901
- San Francisco, CA 94111
- United States
Corporate Office
- 440 Davis Court
- Suite 901
- San Francisco, CA 94111
- United States
Intellistem Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 12-Jul-2024 | Cancelled | Generating Revenue | |||
| 4. Seed Round | 16-Apr-2024 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 26-Apr-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | 28-Oct-2019 | $175K | $175K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Intellistem Patents
Intellistem Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240344026-A1 | Methods to activate gamma delta t cells for antibody dependent cellular cytotoxicity | Pending | 17-Apr-2023 | ||
| WO-2024020700-A1 | Combination therapy with potentiated antigen presenting cells | Inactive | 29-Jul-2022 | ||
| WO-2024020699-A1 | Potentiated antigen presenting cells | Inactive | 29-Jul-2022 | ||
| US-20220193211-A1 | Overexpression of immunoproteasome in host cells for generating antigen-presenting cells | Inactive | 18-Apr-2019 | ||
| WO-2020210915-A1 | Overexpression of immunoproteasome in host cells for generating antigen-presenting cells | Inactive | 18-Apr-2019 | A61K39/3955 |
Intellistem Signals
Intellistem Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| REGEN Capital | Venture Capital | Minority | ||
| MIT Solve | Accelerator/Incubator | |||
| Octane (California) | Accelerator/Incubator | |||
| District 3 Innovation Center | Accelerator/Incubator |
Intellistem FAQs
-
When was Intellistem founded?
Intellistem was founded in 2019.
-
Where is Intellistem headquartered?
Intellistem is headquartered in San Francisco, CA.
-
What is the size of Intellistem?
Intellistem has 4 total employees.
-
What industry is Intellistem in?
Intellistem’s primary industry is Biotechnology.
-
Is Intellistem a private or public company?
Intellistem is a Private company.
-
What is Intellistem’s current revenue?
The current revenue for Intellistem is .
-
How much funding has Intellistem raised over time?
Intellistem has raised $1.38M.
-
Who are Intellistem’s investors?
REGEN Capital, MIT Solve, Octane (California), and District 3 Innovation Center have invested in Intellistem.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process